Cosmo Pharmaceuticals N.V. (ETR:C43)

Market Cap	952.35M
Revenue (ttm)	266.79M
Net Income (ttm)	133.24M
Shares Out	n/a
EPS (ttm)	8.12
PE Ratio	7.15
Forward PE	n/a
Dividend	2.00 (3.42%)
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	44
Open	57.50
Previous Close	57.50
Day's Range	57.50 - 58.00
52-Week Range	52.50 - 86.50
Beta	n/a
RSI	45.79
Earnings Date	Mar 6, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 325
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: C43